Elecoglipron Compared With Placebo in Adults With Certain Types of Heart Failure
Tests elecoglipron against placebo for heart outcomes in adults with HFpEF or HFmrEF.
Plain-language title generated from the registry record
Registry title: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Key facts
- Where
- Anchorage, Annapolis, Arlington, Atlanta, Baltimore, Bethlehem, Beverly Hills, Bossier City, Boston, Bradenton, Bridgeton, Bridgewater, Brooklyn, Buffalo, Burlington, Champaign, Chapel Hill, Chicago, Colorado Springs, Columbus, Covington, Dallas, Dayton, DeSoto, Durham, East Providence, El Paso, Fairhope, Fargo, Flint, Gilbert, Grand Forks, Greensboro, Gurnee, Hallandale, Houston, Humble, Huntington Beach, Huntington Park, Indianapolis, Jacksonville, Kansas City, Kingwood, Lafayette, Lakeland, Lanham, Leavenworth, Lincoln, Loma Linda, Lomita, Mather, Maumee, Media, Melrose Park, Miami, Miami Lakes, Millville, Moline, Morgantown, New Bedford, New Haven, New Orleans, New York, Niles, Northridge, Ocala, Ocoee, Oklahoma City, Owensboro, Oxon Hill, Palmetto Bay, Palo Alto, Philadelphia, Plano, Rapid City, Redding, Redmond, Riverview, Rockford, Rosedale, San Antonio, San Diego, Schaumburg, Sewell, Shreveport, Smithfield, Southfield, Spartanburg, Statesville, Sun City, Tampa, Tarzana, The Bronx, Tomball, Trenton, Troy, Tucker, Tyler, Victoria, Vineland, Waterloo, Wichita, Wilmington, Winfield, Worcester, Yardley, and Zachary, United StatesSee the 107 sites
- Phase
- Phase 3
Where in United States
- AnchorageAnchorage, United StatesNot yet recruiting
- AnnapolisAnnapolis, United StatesNot yet recruiting
- ArlingtonArlington, United StatesNot yet recruiting
- AtlantaAtlanta, United StatesNot yet recruiting
- BaltimoreBaltimore, United StatesNot yet recruiting
- BethlehemBethlehem, United StatesNo longer taking part
- Beverly HillsBeverly Hills, United StatesNot yet recruiting
- Bossier CityBossier City, United StatesNot yet recruiting
- BostonBoston, United StatesNot yet recruiting
- BradentonBradenton, United StatesNo longer taking part
- BridgetonBridgeton, United StatesNot yet recruiting
- BridgewaterBridgewater, United StatesNot yet recruiting
- BrooklynBrooklyn, United StatesTaking people
- BuffaloBuffalo, United StatesNot yet recruiting
- BurlingtonBurlington, United StatesNo longer taking part
- ChampaignChampaign, United StatesNo longer taking part
- Chapel HillChapel Hill, United StatesNot yet recruiting
- ChicagoChicago, United StatesNot yet recruiting
- Colorado SpringsColorado Springs, United StatesNot yet recruiting
- ColumbusColumbus, United StatesNot yet recruiting
- CovingtonCovington, United StatesNot yet recruiting
- DallasDallas, United StatesNot yet recruiting
- DaytonDayton, United StatesNot yet recruiting
- DeSotoDeSoto, United StatesNot yet recruiting
- DurhamDurham, United StatesNot yet recruiting
- East ProvidenceEast Providence, United StatesNot yet recruiting
- El PasoEl Paso, United StatesNot yet recruiting
- FairhopeFairhope, United StatesTaking people
- FargoFargo, United StatesNot yet recruiting
- FlintFlint, United StatesTaking people
- GilbertGilbert, United StatesNot yet recruiting
- Grand ForksGrand Forks, United StatesNot yet recruiting
- GreensboroGreensboro, United StatesNot yet recruiting
- GurneeGurnee, United StatesNot yet recruiting
- HallandaleHallandale, United StatesNot yet recruiting
- HoustonHouston, United StatesNot yet recruiting
- HumbleHumble, United StatesTaking people
- Huntington BeachHuntington Beach, United StatesNot yet recruiting
- Huntington ParkHuntington Park, United StatesNot yet recruiting
- IndianapolisIndianapolis, United StatesNot yet recruiting
- JacksonvilleJacksonville, United StatesNot yet recruiting
- Kansas CityKansas City, United StatesNo longer taking part
- KingwoodKingwood, United StatesNot yet recruiting
- LafayetteLafayette, United StatesNot yet recruiting
- LakelandLakeland, United StatesNot yet recruiting
- LanhamLanham, United StatesNot yet recruiting
- LeavenworthLeavenworth, United StatesNot yet recruiting
- LincolnLincoln, United StatesNot yet recruiting
- Loma LindaLoma Linda, United StatesNot yet recruiting
- LomitaLomita, United StatesTaking people
- MatherMather, United StatesNot yet recruiting
- MaumeeMaumee, United StatesNot yet recruiting
- MediaMedia, United StatesNot yet recruiting
- Melrose ParkMelrose Park, United StatesNot yet recruiting
- MiamiMiami, United StatesNot yet recruiting
- Miami LakesMiami Lakes, United StatesNo longer taking part
- MillvilleMillville, United StatesNot yet recruiting
- MolineMoline, United StatesNot yet recruiting
- MorgantownMorgantown, United StatesNot yet recruiting
- New BedfordNew Bedford, United StatesNot yet recruiting
- New HavenNew Haven, United StatesNot yet recruiting
- New OrleansNew Orleans, United StatesNot yet recruiting
- New YorkNew York, United StatesNot yet recruiting
- NilesNiles, United StatesNot yet recruiting
- NorthridgeNorthridge, United StatesNot yet recruiting
- OcalaOcala, United StatesNot yet recruiting
- OcoeeOcoee, United StatesNo longer taking part
- Oklahoma CityOklahoma City, United StatesNot yet recruiting
- OwensboroOwensboro, United StatesNot yet recruiting
- Oxon HillOxon Hill, United StatesNot yet recruiting
- Palmetto BayPalmetto Bay, United StatesNot yet recruiting
- Palo AltoPalo Alto, United StatesNot yet recruiting
- PhiladelphiaPhiladelphia, United StatesNot yet recruiting
- PlanoPlano, United StatesNo longer taking part
- Rapid CityRapid City, United StatesNot yet recruiting
- ReddingRedding, United StatesNot yet recruiting
- RedmondRedmond, United StatesTaking people
- RiverviewRiverview, United StatesNot yet recruiting
- RockfordRockford, United StatesNot yet recruiting
- RosedaleRosedale, United StatesNot yet recruiting
- San AntonioSan Antonio, United StatesNot yet recruiting
- San DiegoSan Diego, United StatesNot yet recruiting
- SchaumburgSchaumburg, United StatesNot yet recruiting
- SewellSewell, United StatesNot yet recruiting
- ShreveportShreveport, United StatesNot yet recruiting
- SmithfieldSmithfield, United StatesNot yet recruiting
- SouthfieldSouthfield, United StatesNot yet recruiting
- SpartanburgSpartanburg, United StatesNot yet recruiting
- StatesvilleStatesville, United StatesNot yet recruiting
- Sun CitySun City, United StatesNot yet recruiting
- TampaTampa, United StatesNot yet recruiting
- TarzanaTarzana, United StatesNo longer taking part
- The BronxThe Bronx, United StatesNot yet recruiting
- TomballTomball, United StatesTaking people
- TrentonTrenton, United StatesNot yet recruiting
- TroyTroy, United StatesNot yet recruiting
- TuckerTucker, United StatesNot yet recruiting
- TylerTyler, United StatesNot yet recruiting
- VictoriaVictoria, United StatesNot yet recruiting
- VinelandVineland, United StatesNot yet recruiting
- WaterlooWaterloo, United StatesNot yet recruiting
- WichitaWichita, United StatesNot yet recruiting
- WilmingtonWilmington, United StatesNot yet recruiting
- WinfieldWinfield, United StatesNot yet recruiting
- WorcesterWorcester, United StatesNo longer taking part
- YardleyYardley, United StatesNot yet recruiting
- ZacharyZachary, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07761117EU 2026-526304-79-00
- Record updated
- 28 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Inclusion: Left ventricular ejection fraction (LVEF) of > 40% within 12 months prior to screening; Structural heart disease evidence; HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.
Exclusion: Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema; more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition; Major cardiac surgery, coronary revascularization, valvular repair/replacement, AF/AFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization; Clinically significant upper GI condition affecting gastric emptying, drug absorption, or safety/tolerability interpretation; chronic use of drugs directly affecting GI motility; severe disease or prior surgery; Diabetes exclusions:; History of type 1 diabetes; Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy/dysplasia; History of acute or chronic pancreatitis; History/ family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or basal calcitonin ≥35 ng/L at screening; HbA1c ≥10% at screening; On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening; BMI <25 kg/m² at screening; Renal exclusions:; Cardiovascular exclusions:; GI exclusions:; Endocrine exclusions:.